**Indication**
First line treatment of primary CNS lymphoma.

**ICD-10 codes**
Codes with a prefix C85.

**Regimen details**

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 and 6</td>
<td>Rituximab</td>
<td>375mg/m²</td>
<td>IV infusion</td>
</tr>
<tr>
<td>7</td>
<td>Methotrexate</td>
<td>500mg/m²</td>
<td>IV infusion</td>
</tr>
<tr>
<td>7</td>
<td>Methotrexate</td>
<td>3g/m²</td>
<td>IV infusion</td>
</tr>
<tr>
<td>8 onwards</td>
<td>Calcium folinate</td>
<td>As below</td>
<td>IV/PO</td>
</tr>
<tr>
<td>8 and 9</td>
<td>Cytarabine</td>
<td>2g/m² <strong>BD</strong> (12 hours apart)</td>
<td>IV infusion</td>
</tr>
<tr>
<td>10</td>
<td>Thiotepa</td>
<td>30mg/m²</td>
<td>IV infusion</td>
</tr>
</tbody>
</table>

Pre and post hydration required, to commence prior to methotrexate, as below.

**Cycle frequency**
21 days

**Number of cycles**
Up to 4 cycles. Disease should be reassessed after 2 cycles before proceeding to 4 cycles.

**Administration**

**Rituximab** is administered in 500mL sodium chloride 0.9%. The first infusion should be initiated at 50mg/hour and if tolerated the rate can be increased by 50mg/hour every 30 minutes to a maximum of 400mg/hour. Subsequent infusions should be initiated at 100mg/hour and if tolerated increased by 100mg/hour increments every 30 minutes to a maximum of 400 mg/hour.

**Methotrexate pre and post hydration:**
1000mL sodium chloride 0.45%/dextrose 5% with 20mmol potassium chloride and 50mmol sodium bicarbonate should be commenced 8-24 hours prior to methotrexate at a suggested rate of 1000mL over 4 hours and continued concurrently during methotrexate infusion and until calcium folinate rescue is no longer required (see below).

Full dose methotrexate should only be given in the presence of a normal serum creatinine and CrCl ≥ 80mL/min. See below for dose reductions in renal impairment.

Prior to commencing methotrexate, patients must have a urine pH ≥7.0 and a urine output ≥ 100mL/hour. This should be maintained during treatment and until calcium folinate rescue is no longer required. Fluid balance should be closely monitored and urine pH measured hourly. Additional sodium bicarbonate (either added to fluids or given orally) may be required to maintain urine pH ≥7.0.

**Methotrexate** is given in 2 separate doses. Methotrexate 500mg/m² is administered in 250mL sodium chloride 0.9% over 15 minutes. This is then immediately followed by the 3g/m² dose administered in 1000mL sodium chloride 0.9% over 3 hours.
**Calcium folinate** is commenced 24 hours after the start of the first methotrexate infusion at a dose of 15mg/m$^2$ every 3 hours for 6-8 doses. It is administered as an IV bolus or IV infusion in 100mL glucose 5% over 30 minutes. Calcium folinate is then given every 6 hours until serum methotrexate level <0.1μmols/L. It may be given orally after the first 24 hours if the patient is compliant, not vomiting and otherwise without complication. Calcium folinate is available as 15mg and 30mg tablets.

Serum methotrexate levels should be taken 48 hours after the start of the methotrexate infusion and then every 24 hours. If the 48 hour level is >2.0μmols/L the dose of calcium folinate should be doubled. Serum methotrexate levels and U+Es must be checked every 24 hours and urine output and pH every hour. Calcium folinate rescue and urine pH should be maintained ≥7.0 until the methotrexate level is <0.1μmols/L. The dose of calcium folinate should also be increased if serum creatinine increases > 50% from baseline.

**Cytarabine** is administered in 1000mL sodium chloride 0.9% over 3 hours every 12 hours. At least the first dose will run concurrently with the post hydration fluid. A total of 4 doses are given.

**Thiotepa** is administered in 50-100mL sodium chloride (concentration dependent) over 30 minutes.

**Pre-medication**
- Pre-hydration as above.
- Rituximab premedication:
  - Paracetamol 1g PO 60 minutes prior to rituximab infusion
  - Chlorphenamine 10mg IV bolus 15 minutes prior to rituximab infusion
  - Dexamethasone 8mg IV bolus or hydrocortisone 100mg IV bolus 15 minutes prior to rituximab infusion

**Emetogenicity**
This regimen has high emetic potential.

**Additional supportive medication**
- Allopurinol 300mg OD (100mg OD if CrCl < 20mL/min) for the first 2 weeks.
- Antiemetics as per local policy.
- Mouthwashes as per local policy.
- H$_2$ antagonist or PPI as per local policy.
- GCSF from day 11 as per local policy.
- Antiviral, antifungal and PCP prophylaxis as per local policy.
- Prednisolone 0.5% eye drops QDS for 7 days starting on day 8 (to avoid chemical conjunctivitis from high-dose cytarabine).
- Calcium folinate as above.

**Extravasation**
Cytarabine, thiotepa and rituximab neutral (Group 1)
Methotrexate is an inflammatant (Group 2)

**Investigations – pre first cycle**

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Validity period (or as per local policy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBC (with film)</td>
<td>72 hours and daily during treatment</td>
</tr>
<tr>
<td>U+E (including creatinine)</td>
<td>72 hours and daily during treatment</td>
</tr>
<tr>
<td>LFTs</td>
<td>72 hours and twice weekly during treatment</td>
</tr>
</tbody>
</table>

Consider echocardiogram and/or lung function tests if clinically indicated.
Hepatitis B and C serology
HIV status
Investigations – pre subsequent cycles

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Validity period</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBC</td>
<td>Twice a week between cycles and 72 hours before next cycle</td>
</tr>
<tr>
<td>U+E (including creatinine)</td>
<td>Twice a week between cycles and 72 hours before next cycle</td>
</tr>
<tr>
<td>LFTs</td>
<td>Twice a week between cycles and 72 hours before next cycle</td>
</tr>
<tr>
<td>Serum methotrexate levels</td>
<td>As above</td>
</tr>
</tbody>
</table>

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer must be given by prescriber/consultant

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophils</td>
<td>&gt; 1.0 x 10^9/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>&gt; 100 x 10^9/L</td>
</tr>
<tr>
<td>Creatinine Clearance (CrCl)</td>
<td>≥ 80 mL/min</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>≤ 1.5 x ULN</td>
</tr>
<tr>
<td>AST/ALT</td>
<td>≤ 3.5 x ULN</td>
</tr>
</tbody>
</table>

If pleural effusion or ascites present, methotrexate should not be given due to risk of accumulation and prolonged toxicity.

Dose modifications

- **Haematological toxicity**
  Grade 3-4 cytopenias are expected with this regimen. Delay treatment if neutrophils < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L until count recovery.

- **Renal impairment**
  Discuss with consultant as some circumstances may warrant 100% dose.

<table>
<thead>
<tr>
<th>CrCl (mL/min)</th>
<th>Methotrexate dose</th>
<th>Cytarabine dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 80</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>60-79</td>
<td>65%</td>
<td></td>
</tr>
<tr>
<td>45-59</td>
<td>50%</td>
<td>60%</td>
</tr>
<tr>
<td>30-44</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Discontinue</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

If patient has raised creatinine and methotrexate level > 2.0 μmols/L, seek specialist renal advice.

There is limited information regarding thiotepa in renal impairment, consider dose reduction and use with caution.

- **Hepatic impairment**
  Discuss with consultant as some circumstances may warrant 100% dose.

<table>
<thead>
<tr>
<th>Bilirubin (x ULN)</th>
<th>AST/ALT (x ULN)</th>
<th>Methotrexate dose</th>
<th>Cytarabine dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1.5</td>
<td>and</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>1.5 – 3</td>
<td>and</td>
<td>100%</td>
<td>50%</td>
</tr>
<tr>
<td>3 – 5</td>
<td>or</td>
<td>75%</td>
<td>50%</td>
</tr>
<tr>
<td>&gt; 5</td>
<td></td>
<td>Discontinue</td>
<td>50%</td>
</tr>
</tbody>
</table>

Cytarabine dose should be reduced to 50% if bilirubin > 1.5 x ULN. Doses may be escalated in subsequent cycles in the absence of toxicity (consultant decision).

Note: raised transaminases and/or bilirubin may occur for up to 2 weeks after methotrexate.

There is limited information regarding thiotepa in hepatic impairment, consider dose reduction and use with caution.
**Other toxicities**

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Definition</th>
<th>Methotrexate</th>
<th>Cytarabine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Grade 3-4</td>
<td>Interrupt treatment until resolved</td>
<td>Interrupt treatment until resolved</td>
</tr>
<tr>
<td>Coagulation</td>
<td>Grade 4</td>
<td>75% dose</td>
<td>75% dose</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Grade 4</td>
<td>75% dose</td>
<td>75% dose</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Grade 4</td>
<td>75% dose</td>
<td>75% dose</td>
</tr>
</tbody>
</table>

If pleural effusion or ascites present, methotrexate should not be given due to risk of accumulation and prolonged toxicity.

**Adverse effects** - for full details consult product literature/ reference texts

- **Serious side effects**
  - Myelosuppression
  - Cardiotoxicity
  - Neurotoxicity
  - Acute pulmonary toxicity
  - Nephrotoxicity
  - Hepatotoxicity
  - CNS toxicity (cytarabine)
  - Infertility

- **Frequently occurring side effects**
  - Myelosuppression
  - Diarrhoea
  - Infusion related reactions (rituximab)
  - Fatigue
  - Nausea and vomiting
  - Mucositis, stomatitis
  - Alopecia
  - Conjunctivitis (cytarabine)
  - Dizziness, headache, blurred vision (thiotepa)

- **Other side effects**
  - Haemorrhagic cystitis
  - Cytarabine syndrome (fever, myalgia, rash)
  - Hyperglycaemia
  - Myalgia, bone pain

**Significant drug interactions** – for full details consult product literature/ reference texts

- **Warfarin/coumarin anticoagulants**: increased or fluctuating anticoagulant effects. Avoid if possible, consider switching patient to a low molecular weight heparin during treatment or if the patient continues taking an oral anticoagulant monitor the INR at least once a week and adjust dose accordingly.

- **Methotrexate**:
  - Avoid all nephrotoxic agents
  - **NSAIDS**: increase risk of methotrexate toxicity – avoid
  - **Omeprazole**: potential to increase methotrexate levels
  - **Co-trimoxazole**: if used concurrently may cause severe bone marrow depression – avoid
  - **Theophylline**: may reduce theophylline clearance – avoid
  - **Acetretin**: increased risk of hepatitis
  - **Penicillins**: may reduce excretion of methotrexate levels
Cytarabine:
Digoxin: cytarabine may affect plasma digoxin levels – consider monitoring

Thiotepa:
**CYP2B6 inhibitors** (including clopidogrel) and **CYP3A4 inhibitors** (includingazole antifungals and macrolide antibiotics) may increase plasma concentration of thiotepa and reduce concentration of active metabolite; avoid concomitant use.

**Cytochrome P450 inducers** (including rifampicin and carbamazepine) may increase metabolism of thiotepa and therefore increase plasma concentration of the active metabolite.

Additional comments
It is expected that patients receiving high dose methotrexate will develop hypertransaminasaemia and occasionally hyperbilirubinaemia. These elevations can last up to 2 weeks following the methotrexate infusion. Persistent hyperbilirubinaemia and/or grade 3-4 hypertransaminasaenia for longer than 3 weeks should result in discontinuation of treatment.

References
- Summary of Product Characteristics Cytarabine (Pfizer) accessed 11 Nov 2015 via www.medicines.org.uk
- Summary of Product Characteristics Rituximab (Roche) accessed 11 Nov 2015 via www.medicines.org.uk
- Ferreri AJ et al. Addition of thiotepa and rituximab to antimetabolites significantly improves outcomes in primary CNS lymphoma: first randomization of the IELSG32 trial. Presented at: 13th International Conference on Malignant Lymphoma; June 17-20, 2015; Lugano, Switzerland. Abstract 009

Written/reviewed by: Dr D Mannari (Consultant Haematologist, Yeovil District Hospital)
Checked by: Sarah Murdoch (Senior Oncology Pharmacist, SW Strategic Clinical Network)
Authorised by: Dr J Braybrooke (Consultant Oncologist, UHBristol NHS Trust, SW Strategic Clinical Network)
Date: December 2015